Genetic polymorphisms of HO-1 and COX-1 are associated with aspirin resistance defined by light transmittance aggregation in Chinese Han patients

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 5, 2013, Pages 513-521

  Li, Xiao Li ^a,b   Cao, Jian ^a   Fan, Li ^a   Wang, Qiang ^b   Ye, Ling ^a   Cui, Chun Ping ^c   Wang, Ya Zhen ^b   Liu, Lin ^a   Li, Bin ^b   Wu, Ruo Jun ^b   Zhou, Feng Chun ^b   Zhang, Jun Hong ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 309TH HOSPITAL OF PLA   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

aspirin resistance; cyclooxygenase 1 (COX 1); hemoxygenase 1 (HO 1); platelet aggregation; single nucleotide polymorphism (SNP)

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HEME OXYGENASE 1;

ALLELE; ARACHIDONIC ACID METABOLISM; ARTICLE; ASPIRIN RESISTANCE; BLOOD SAMPLING; CARDIOLOGY; CEREBROVASCULAR ACCIDENT; CHINESE; CORONARY ARTERY DISEASE; DNA DETERMINATION; DRUG EFFECT; DRUG RESISTANCE; FREQUENCY ANALYZER; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; LIGHT TRANSMITTANCE AGGREGATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ASPIRIN RESISTANCE; CYCLOOXYGENASE-1 (COX-1); HEMOXYGENASE-1 (HO-1); PLATELET AGGREGATION; SINGLE-NUCLEOTIDE POLYMORPHISM (SNP);

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DRUG RESISTANCE; FEMALE; HEME OXYGENASE-1; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCATTERING, RADIATION;

EID: 84884259247     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612444002     Document Type: Article

References (34)

1. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 373 (9678). 1849-1860
2. Rafferty M, Walters MR, Dawson J. Anti-platelet therapy and aspirin resistance clinically and chemically relevant?. Curr Med Chem. 2010 ; 17 (36). 4578-4586
3. Feher G, Feher A, Pusch G, et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol. 2010 ; 2 (7). 171-186
4. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol. 2004 ; 43 (6). 1127-1129
5. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008 ; 336 (7637). 195-198
6. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007 ; 167 (15). 1593-1599
7. O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation. 2001 ; 103 (25). 3051-3056
8. Sneader W. The discovery of aspirin: a reappraisal. BMJ. 2000 ; 321 (7276). 1591-1594
9. Frelinger A, Furman MI, Linden MD, et al. Residual AA-induced platelet activation via an adenosine diphosphate-dependent but COX-1- and COX-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006 ; 113 (25). 2888-2896
10. Peng L, Mundada L, Stomel JM, et al. Induction of heme oxygenase-1 expression inhibits platelet-dependent thrombosis. Antioxid Redox Signal. 2004 ; 6 (4). 729-735
11. Gurbel P, Bliden K, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007 ; 26 (115). 3156-3164
12. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009 ; 2: 2.12
13. Agúndez, Martínez JA, Pérez-Sala D, et al. Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009 ; 10 (9). 998-1008
14. Lev EI, Patel RT, Guthikonda S, et al. Genetic polymorphisms of the platelet receptors P2Y (12), P2Y (1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res. 2007 ; 119 (3). 355-360
15. Szczeklik A, Musiał J, Undas A, et al. Aspirin resistance. J Thromb Haemost. 2005 ; 3 (8). 1655-1662
16. Fujiwara T, Ikeda M, Esumi K, et al. Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J. 2007 ; 7 (6). 395-403
17. Oh SH, Kim YH, Park SM, et al. Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. Pharmacogenomics J. 2011 ; 12 (3). 351-363
18. Song J, Sumiyoshi S, Nakashima Y, et al. Overexpression of heme oxygenase-1 in coronary atherosclerosis of Japanese autopsies with diabetes mellitus: Hisayama study. Atherosclerosis. 2009 ; 202 (2). 573-581
19. McGeer PL, McGeer EG, Yasojima K. Expression of COX-1 and COX-2 mRNA in atherosclerotic plaques. Exp Gerontol. 2002 ; 37 (7). 925-929
20. Nowell SA, Leakey JE, Warren JF, et al. Identification of enzymes responsible for the metabolism of heme in human platelets. J Biol Chem. 1998 ; 273 (50). 33342-33346
21. Maree AO, Curtin RJ, Chubb A. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. Thromb Haemost. 2005 ; 3 (10). 2340-2345
22. Goodman T, Sharma P, Ferro A. The genetics of aspirin resistance. Int J Clin Pract. 2007 ; 61 (5). 826-834
23. Arisawa T, Tahara T, Shibata T, et al. Genetic polymorphisms of cyclooxygenase-1 (COX-1) are associated with functional dyspepsia in Japanese women. J Womens Health. 2008 ; 17 (6). 1039-1043
24. Arisawa T, Tahara T, Shibata T, et al. Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int J Mol Med. 2007 ; 20 (3). 373-378
25. Eldika N, Yerra L, Chi DS, et al. Atherosclerosis as an inflammatory disease: implications for therapy. Front Biosci. 2004 ; 9: 2764-2777
26. Patrignani P, Sciulli M, Manarini S, et al. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol. 1999 ; 50 (4). 661-667
27. Fürst R, Blumenthal SB, Kiemer AK, et al. Nuclear factor-kappa B-independent anti-inflammatory action of salicylate in human endothelial cells: induction of heme oxygenase-1 by the c-jun N-terminal kinase/activator protein-1 pathway. J Pharmacol Exp Ther. 2006 ; 318 (1). 389-394
28. Grosser N, Abate A, Oberle S, et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003 ; 308 (4). 956-960
29. Pae HO, Lee YC, Chung HT. Heme oxygenase-1 and carbon monoxide: emerging therapeutic targets in inflammation and allergy. Recent Pat Inflamm Allergy Drug Discov. 2008 ; 2 (3). 159-165
30. Stocker R, Perrella MA. Heme oxygenase-1: a novel drug target for atherosclerotic diseases?. Circulation. 2006 ; 114 (20). 2178-2189
31. Lavrovsky Y, Schwartzman ML, Levere RD, et al. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci USA. 1994 ; 91 (13). 5987-5991
32. Alam J, Cook JL. How many transcription factors does it take to turn on the heme oxygenase-1 gene?. Am J Respir Cell Mol Biol. 2007 ; 36 (2). 166-174
33. Exner M, Minar E, Wagner O, et al. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med. 2004 ; 37 (8). 1097-1104
34. Levonen AL, Vähäkangas E, Koponen JK, et al. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. Circulation. 2008 ; 117 (16). 2142-2150